Aerie Pharmaceuticals Inc
NASDAQ:AERI
Aerie Pharmaceuticals Inc
Free Cash Flow
Aerie Pharmaceuticals Inc
Free Cash Flow Peer Comparison
Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Aerie Pharmaceuticals Inc
NASDAQ:AERI
|
Free Cash Flow
$2.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$18.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$12.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$5.1B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-11%
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$11B
|
CAGR 3-Years
18%
|
CAGR 5-Years
6%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
-$3.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Aerie Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
2.6m
USD
Based on the financial report for Sep 30, 2022, Aerie Pharmaceuticals Inc's Free Cash Flow amounts to 2.6m USD.